Gaucher's disease


Also found in: Dictionary, Thesaurus, Medical, Legal, Wikipedia.

Gaucher's disease

(gōshāz`), rare genetic disease involving a deficiency of an enzyme, glucocerebrosidase, which normally breaks down certain body glycolipids (i.e., lipidslipids,
a broad class of organic products found in living systems. Most are insoluble in water but soluble in nonpolar solvents. The definition excludes the mineral oils and other petroleum products obtained from fossil material.
..... Click the link for more information.
 (fats) that have a sugar molecule attached). There are three types of the disease. In all three types, the enzyme deficiency results in a buildup of the glycolipid glucocerebroside in the bone marrow, liver, and spleen, resulting in anemia and other blood disorders, bone pain and pathologic fractures, and enlarged liver and spleen. In Type II, the central nervous system is also affected. Patients are severely mentally retarded and have difficulty controlling their muscles. The disease progresses quickly from birth and usually is fatal by the age of two. In Type III disease, the course is chronic and central nervous system involvement begins later on. The symptoms are the same as those of Type II. Type I disease occurs most often in Ashkenazi Jews of Eastern European origin, Type III in people of Swedish origin.

There is no cure for Gaucher's disease, but in 1991 an enzyme replacement drug, Ceridase, was approved and allowed people with Type I disease (the most common) to live nearly normal lives. Ceridase was extracted from human placental tissue in very small amounts and the supply was limited. In 1994, a genetically engineered version of the drug (Cerezyme) was introduced. Both were developed as orphan drugs and were controversial because of their costliness.

Gaucher's disease

[gō′shāz di‚zēz]
(medicine)
A rare chronic, probably hereditary disease in which cells loaded with cerebrosides become localized in reticuloendothelial tissue and eventually cause tissue destruction; manifestations include enlargement of the spleen, bronzing of the skin, and anemia. Also known as cerebroside lipoidosis; familial splenic anemia.
References in periodicals archive ?
LEAVE YOUR QUERIES @ Gaucher's Disease - Pipeline Review, H2 2015
Reasons to buy Gaucher's Disease - Pipeline Review, H2 2014 market research report:
Gaucher's disease is the most common genetic disease among the Ashkenazi Jewish population of Eastern European ancestry.
Pyogenic osteomyelitis versus pseudo-osteomyelitis in Gaucher's disease.
2] Fortunately, considering the severity of the disease and the great expense of treatment, the number of patients afflicted is much more limited than the 2,000-3,000 individuals with Gaucher's Disease.
Coverage of the Gaucher's Disease pipeline on the basis of route of administration and molecule type.
Previous attempts to treat Gaucher's disease with injections of the fully functioning enzyme failed because scientists couldn't get enough of the lifesaving substance into the patients' macrophages.
studied 47 unrelated patients with Type I Gaucher's disease.
Vevesca(TM) is in late stage clinical trials for the treatment of Gaucher's disease and other glycolipid storage diseases.
The investigators cloned the sequence of chemical subunits that determine protein production for a normal glucocerebrosidase gene and compared it with a sequence cloned from a patient with type 2 Gaucher's disease.
The launch of new drugs in the Gaucher's disease and Fabry disease markets, coupled with increased awareness amongst patients and physicians, is expected to increase revenues over the forecast period.
There are estimated to be at least four thousand children with Gaucher's Disease in the United States and an equal number outside the United States.